Answers are grounded in this paper and cite their sources.
Pregnancy-associated hyperpigmentation represents one of the most frequent dermatological conditions observed during gestation, with melasma being its most clinically significant form. Its pathogenesis is multifactorial and involves complex interactions between hormonal fluctuations, particularly estrogen, progesterone, and melanocyte-stimulating hormone, ultraviolet and visible light exposure, genetic predisposition, inflammatory mediators, oxidative stress, and dysregulated melanogenesis. Clinically, it presents as symmetric hyperpigmented macules and patches predominantly affecting the face, with additional involvement of other sun-exposed and hormonally sensitive areas. Although generally benign and often showing partial or complete postpartum regression, pregnancy-related hyperpigmentation may persist or recur, leading to considerable cosmetic concern and psychosocial distress. Current management during pregnancy is primarily preventive, with strict photoprotection as the cornerstone strategy, while postpartum treatment includes topical depigmenting agents, combination therapies, and emerging safer alternatives with improved efficacy and tolerability profiles. A comprehensive understanding of its epidemiology and underlying mechanisms is essential for optimizing prevention and individualized management strategies.
No takes yet. Share an insight, caveat, or question.
Yuliya Fedorchenko (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: